Effects of using electronic cigarettes on nicotine delivery and cardiovascular function in comparison with regular cigarettes.

Plain-language guide to PMID 25460033 (2015): single-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 25460033
Journal: Regulatory toxicology and pharmacology : RTP
Year: 2015
Study type: Randomized Controlled Trial
Authors: Yan XS et al. (2 authors)
DOI: 10.1016/j.yrtph.2014.11.004

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

This clinical study was designed to characterize e-cig users' exposure to nicotine, and to investigate the acute effects of e-cigs on the hemodynamic measurements (blood pressure and heart rate) in comparison with the effects of regular smoking.

Why It Was Studied

The development of electronic cigarettes (e-cigs) has the potential to offer a less harmful alternative for tobacco users.

Who Took Part

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

Five e-cigs and one Marlboro® cigarette were randomized for twenty-three participants under two exposure scenarios from Day 1 to Day 11: half-hour controlled administration and one hour ad lib use.

How the Study Was Run

In design terms this was a randomized, single-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Only one side, usually the participants, was kept unaware of whether Therapeutic nicotine (patch, non-peptide) was given.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

What Was Measured

Topics PubMed links to this paper include Blood Pressure, Carbon Monoxide, Electronic Nicotine Delivery Systems, Heart Rate, Nicotine and Tobacco Products.

Author keywords: Cardiovascular function, Electronic cigarette and Smoking.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2015 (Regulatory toxicology and pharmacology : RTP), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.